UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 7, 2023
Akoya Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40344 | 47-5586242 |
(State or other jurisdiction
of incorporation) | (Commission
File Number) | (IRS Employer
Identification No.) |
100 Campus Drive, 6th Floor Marlborough, MA
(Address of principal executive offices) | 01752
(Zip Code) |
(855) 896-8401
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading
Symbol | | Name of each exchange on which registered |
| Common stock, par value $0.00001 per share | | AKYA | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In connection with the reduction in force described under Item 8.01 below, on June 7, 2023, each of Marilee Moy and Ehab El-Gabry were terminated as Chief People Officer and Chief Medical Officer, respectively, of Akoya Biosciences, Inc. (the “Company”). Unless otherwise agreed, Ms. Moy and Dr. El-Gabry are entitled to severance payments pursuant to the Company’s Severance Plan as described in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on April 20, 2023. The terminations were not the result of any disagreement between the Company and Ms. Moy or Dr. El-Gabry, respectively.
Item 7.01 Regulation FD.
On June 7, 2023, the Company updated its corporate presentation slide deck. A copy of the slide deck is furnished as Exhibit 99.1 hereto.
Item 8.01 Other Events.
On June 7, 2023, the Company executed a reduction in force in connection with certain operating expense cost savings initiatives.
Slides 8, 11 and 14 included in Exhibit 99.1 are incorporated by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 7, 2023 | Akoya Biosciences, Inc. |
| | | |
| | By: | /s/ Brian McKelligon |
| | | Brian McKelligon |
| | | Chief Executive Officer |
